P16INK4a as a progression/regression tumour marker in LSIL cervix lesions: our clinical experience.

CONCLUSION: p16l4a should help to identify which LSIL cases are inclined to the progression of the disease and focalize which patients are eligible for specific treatment. PMID: 29787011 [PubMed - in process]
Source: European Journal of Gynaecological Oncology - Category: OBGYN Tags: Eur J Gynaecol Oncol Source Type: research